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Key messages 33 
 34 
What is the key question? 35 
 36 
Is there a significant genetic component to the occurrence of lung cancer and is the 37 
genetic influence modified by smoking and age? 38 
 39 
What is the bottom line? 40 
 41 
The interplay between genes and tobacco smoking in the etiology of lung cancer has 42 
remained controversial, and we disentangle genetic and environmental causes in cancer 43 
while taking smoking status into account. 44 
 45 
Why read on? 46 
 47 
Our study shows that tobacco exposure causes lung cancer even when adjusting for 48 
genetic factors. Interactions between genes and environmental exposure in the 49 
development of lung cancer are not supported from the largest twin cohort study with 50 
longest follow-up ever. Familial effects have decreased influence with increasing age. 51 
 52 
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Abstract 56 
Background  57 
We aimed to disentangle genetic and environmental causes in lung cancer while 58 
considering smoking status.  59 
Methods 60 
Four Nordic Twin Cohorts (43,512 monozygotic (MZ) and 71,895 same sex dizygotic 61 
(DZ) twin individuals) had smoking data before cancer diagnosis. We used time-to-event 62 
analyses accounting for censoring and competing risk of death to estimate incidence, 63 
concordance risk and heritability of liability to develop lung cancer by smoking status.  64 
Results  65 
During a median of 28.5 years of follow-up we recorded 1,508 incident lung cancers. Of 66 
the 30 MZ and 28 DZ pairs concordant for lung cancer, nearly all were current smokers at 67 
baseline and only one concordant pair was seen among never smokers.  Among ever 68 
smokers the case-wise concordance of lung cancer, that is the risk before a certain age 69 
conditional on lung cancer in the co-twin before that age was significantly increased 70 
compared with the cumulative incidence for both MZ and DZ pairs. This ratio, the 71 
relative recurrence risk, significantly decreased by age for MZ, but was constant for DZ 72 
pairs.  Heritability of lung cancer was 0.41 (95%CI 0.26–0.56) for currently smoking and 73 
0.37 (95%CI 0.25–0.49) for ever smoking pairs. Among smoking discordant pairs, the 74 
pairwise hazard ratio for lung cancer of the ever smoker twin compared to the never 75 
smoker cot-win was 5.4 (95%CI 2.1–14.0) in MZ pairs and 5.0 (95%CI 3.2–7.9) in DZ 76 
pairs.  77 
Conclusions 78 
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The contribution of familial effects appears to decrease by age. The discordant pair 79 
analysis confirms that smoking causes lung cancer.  80 
 81 
82 
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Introduction 83 
Smoking is the primary cause of lung cancer globally, though several other 84 
environmental exposures play a role.1 The estimated heritable genetic contribution to 85 
variation in risk to lung cancer overall has been modest in family (heritability estimate of 86 
0.08)2 and twin (0.263 and 0.184) studies. Genome-wide association (GWA) studies 87 
further suggest that some gene loci are associated with lung cancer in both smokers and 88 
non-smokers, while other variants, such as the functional D398N (rs16969968) variant in 89 
CHRNA5, are associated with lung cancer only among smokers.5,6 Thus, the heritability 90 
of  lung cancer may vary as a function of smoking, but the differential effect of smoking 91 
on genetic variation underlying development of lung cancer has not been quantified.  92 
To this end, our aim is to estimate the heritability of liability to lung cancer based 93 
on the largest twin cohort to date, the Nordic Twin Study of Cancer (NorTwinCan)4, 94 
which extends the Lichtenstein (2000)3 study with longer follow-up and new birth 95 
cohorts and refined methodology.  We sought to estimate the heritability in the liability to 96 
lung cancer and whether it is modified by smoking or age.  97 
 98 
Methods 99 
Material 100 
NorTwinCan includes population-based cohorts from the Danish, Finnish, 101 
Norwegian, and Swedish twin registries.7 Each twin has an individually unique national 102 
registration number, allowing for linkage to the national cancer and mortality registries 103 
with complete follow-up, drop-out being only due to death or emigration. Lung cancer 104 
occurrence was obtained from the national cancer registries and computed from the 105 
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baseline when smoking status was determined until the end of follow-up (Table 1). In all 106 
cohorts, zygosity - monozygotic (MZ) or dizygotic (DZ) - was determined at baseline by 107 
validated questionnaire methodology, which classifies more than 95% of twin pairs 108 
correctly.3 Twins, who have not replied to the questionnaires, as well as a minority 109 
providing inconsistent responses, are classified as unknown zygosity (UZ). The ethics 110 
committees for each country approved the study. 111 
Given the major role of smoking in the etiology of lung cancer, our analysis 112 
includes twin individuals of known zygosity from the Danish, Finnish, Norwegian, and 113 
Swedish registries, where data on smoking status was available prior to lung cancer 114 
diagnosis. We excluded individuals from opposite-sex DZ pairs as data from them have 115 
not been as comprehensively collected. For individuals who reported smoking behavior 116 
on more than one questionnaire, we used the earlier information. 117 
Characteristics of the four national twin cohorts included in the analyses are 118 
summarized in Table 1. We classified the participants as never smokers, ever smokers 119 
(former or current at time of questionnaire) and current smokers based on the survey 120 
items used to assess smoking status. Smoking data in the Danish cohort came from the 121 
eight questionnaire surveys conducted from 1959 to 2002.8–10 In Finland smoking data 122 
came primarily from the first questionnaire survey in 1975, but some twins who had not 123 
replied in 1975 responded to a questionnaire survey in 1981.11,12 In the Norwegian cohort 124 
smoking data came from three questionnaire surveys in 1980–1982 & 1990–92 & 125 
1998.13,14 In the Swedish cohort smoking data came from questionnaire surveys in 1961, 126 
1967, 1970, and 1973.15,16 127 
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We included individuals with histologically confirmed lung cancer.  Among those 128 
with smoking data, we recorded a total of 1,508 incident lung cancers with a mean 129 
follow-up time of 25.2 years (21.0 years in lung cancer patients).  130 
 131 
Statistical analysis 132 
After defining cohort-specific dates of entry and follow-up, we accounted for left-133 
truncation from variable initiation of cancer registration and right-censoring among those 134 
censored at the end of follow-up, and lost to follow-up due to emigration (<2%). We 135 
examined the individual risk of lung cancer diagnosis by age by estimating cumulative 136 
lung cancer, incidence17 and lifetime risk as the cumulative incidence (the probability of 137 
lung cancer) by age 80 years. We modeled potential competing deaths18,19 which allows 138 
estimation of lung cancer risk in a twin given the occurrence of other disease in his/her 139 
co-twin.  We obtained the case-wise concordances by age18,19 (see supplementary 140 
material for details) as well as relative recurrence risks in MZ and DZ pairs and the 141 
multilocus index.20,21  142 
We extended standard biometrical modelling methods to address issues of 143 
censoring at follow-up7,22 . Results would agree with those obtained from standard 144 
models for twin data18,23,24 if no censoring  were present. Quantitative models were 145 
analyzed to estimate the magnitude of variation explained by genetic and environmental 146 
influences18 underlying the liability to develop lung cancer by smoking status. The 147 
relative magnitude of genetic influences on variation in liability to lung cancer is thus 148 
estimated among pairs in which neither had ever smoked, among pairs where both co-149 
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twins are ever (former or current) smokers and among pairs in which both co-twins are 150 
current smokers.  151 
We use information on lung cancer incidence in MZ and DZ pairs to decompose 152 
variation into additive genetic effects (A), dominant genetic effects (which represent 153 
deviations of the heterozygote genotype from the mean of the homozygote genotype) (D), 154 
common environmental effects (C), and individually unique environmental effects (E). 155 
Within-pair covariance of liability is expressed as κ var(A) + γ var(D) +var(C), where κ = 156 
γ = 1 for MZ pairs and κ = 1/2 and γ = 1/4 for DZ pairs.18  We tested a series of models 157 
sequentially to assess the significance of specific parameters. We estimated measurement 158 
error in E which is the component of variance that does not contribute to within-pair 159 
resemblance. Dominance effects are, typically, biologically implausible in the absence of 160 
additive effects. The primary models are thus the ACE and ADE models, as well as their 161 
sub-models AE, CE, and E. We assessed the fit of the sub-models by the Akaike 162 
information criterion22. 163 
We tested for equal thresholds (i.e., normal quantiles of prevalence) between MZ 164 
and DZ twins, which is equivalent to assuming that the risk of disease does not differ by 165 
zygosity.  We tested for constant relative recurrence risk (RRR) over age by grouping 166 
into five-year interval from age 65 to 90 years of age for MZ and DZ pairs. To correct for 167 
possible bias due to censoring, individuals were assigned weights obtained by calculating 168 
the inverse probability of being censored at time of follow-up7,18,19,22  Estimates have not 169 
been adjusted for the effect of left-truncation that would cause an upwards bias, which is 170 
not yet feasible for the approach. 171 
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For gene and smoking status interaction the magnitude on liability scale could not 172 
be estimated due to having one concordant pair among all never-never and never-ever 173 
smoking pairs. The presence of genetic interaction with smoking status was therefore 174 
investigated by comparing observed concordance in strata of smoking status  to the 175 
expected when assuming same variance components on the liability scale as in ever-ever 176 
pairs but using smoking-status specific cumulative incidence by age as well as follow-up 177 
time of the specific pairs in the cohort. This procedure leads to an approximate test, 178 
which we later refer to as the binomial test, and takes into account the smoking-status 179 
specific cumulative incidence by age, as well as follow-up time of the specific pairs in the 180 
cohort and we then computed the probability that a randomly selected pairs were 181 
concordant using the dependence parameters of the liability threshold model for the ever-182 
ever pairs. 183 
Among pairs in which one twin was a smoker and the other was not, we computed 184 
within pair hazard ratios for the association of smoking with lung cancer using a Cox 185 
model with pair-specific baseline hazard functions. Given that MZ pairs share their 186 
genomic sequence, an association of smoking with lung cancer risk within such pairs is 187 
independent of genetic liability. This hypothesis has historically competed with the 188 
hypothesis25 of shared genes underlying both smoking and lung cancer. The statistical 189 
program R was used for all analyses with the package mets.26  190 
 191 
 192 
193 
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Results 194 
Among those with smoking data, we recorded 1,508 incident lung cancers among 195 
a total of 115,407 twin (43,512 MZ and 71,895 DZ) individuals.  Forty-seven percent 196 
were never smokers (n=54238), 16% former smokers (n=18,231) and 37% current 197 
smokers (n=42,938) at baseline. Figure 1 shows the cumulative incidence of lung cancer 198 
by smoking status (never, former, current) and sex. The risk of lung cancer diagnosis 199 
before 80 years of age is estimated at 0.6% (95% CI 0.5%–0.7%) among never smokers, 200 
2.0% (1.7%–2.3%) among former and 5.7% (5.4%–6.0%) among current smokers 201 
adjusting for censoring and competing risk of death.  The only sex difference is seen 202 
among smokers. There was no difference in risk between MZ and DZ twin individuals.   203 
The numbers of pairs concordant and discordant for lung cancer incidence are 204 
presented in Table 2 for those with smoking data (n=50,595 pairs with smoking status on 205 
both twins) overall and further classified by smoking status.   206 
Among twin pairs where both are ever smokers, the risk of lung cancer in a twin 207 
before a given age given that his or her co-twin also has lung cancer before that age, the 208 
case-wise concordance by age is depicted in Figure 2 in both MZ and DZ pairs, as well as 209 
the cumulative incidence of lung cancer by age in individuals.  The case-wise 210 
concordance risk was larger in MZ twins than the individual cumulative incidence risk, 211 
testing for a difference from the cumulative incidence across the five year age intervals 212 
(chisq=22.1, df=6, p=0.001). For the DZ twins we found that the case-wise concordances 213 
were borderline significantly different from the cumulative incidence (chisq=13.4, df=6, 214 
p=0.04). The estimated case-wise concordance at 90 years of age was 0.20 (0.13-0.27) for 215 
MZ pairs and 0.13 (0.08-0.17) for DZ pairs. 216 
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This excess risk of MZ and DZ pairs of the case-wise concordance relative to the 217 
population based individual cumulative incidence of lung cancer, the relative recurrence 218 
risk (also known as the lambda value) is depicted in Figure 3 and demonstrates the 219 
presence of familial effects at all ages. The RRR is higher at younger ages, in fact the 220 
lung cancer risk is increased 10.2 -fold (3.2-17.2) at 65 years of age and decreases 221 
significantly to a 3.6 (2.3-4.9) -fold increase at 90 years of age if a MZ co-twin is 222 
diagnosed (p-value = 0.04, test for trend). The RRR is suggested to be constant by age for 223 
DZ twins (p-value = 0.25, test for trend) (Figure 3). (A table of relative risks by age-224 
group is provided in supplemental Table 1.) We tested if the absolute differences of the 225 
MZ and DZ curves at each five-year interval from age 65 to age 90 years of age were 226 
significantly different, which there was no sign of (p-value=0.21). Our results are thus 227 
consistent with the hypothesis of rather strong familial influences that do not increase 228 
across age. We hypothesize that the genetic part of the familial influence may become 229 
weaker by age. 230 
We then examined evidence for genetic factors in the liability to develop lung 231 
cancer by smoking status. Among pairs in which neither had ever smoked (7,871 MZ 232 
pairs and 10,768 DZ pairs), there was one lung cancer concordant MZ pair with 43 MZ 233 
and 59 DZ lung cancer discordant pairs.  Heritability could not be estimated. However, 234 
the dependence in the never-never and never-ever pairs was not significantly different 235 
from the dependence among the ever-ever pairs (p=0.28, binomial test of observing more 236 
than one concordant pair of lung cancer).  237 
The overall estimate of familial aggregation (genetic variance and shared 238 
environment component) for lung cancer liability is 44% with 38% (0.05- 0.72) of 239 
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variability attributed to genetic effects.  When adjusted for smoking status, effects of 240 
country and sex, variability attributed to genetic effects was 34% (0.00-0.70) (Table 3). A 241 
comparison of the MZ and DZ tetrachoric within-pair correlations in liability to develop 242 
lung cancer (Table 3) adjusting for age, sex, country and smoking, and further adjustment 243 
for censoring hypothesizing equal correlations, gave a p-value of 0.07 (Wald test). 244 
Among the pairs where both twins are ever (current or former) smokers, the heritability 245 
estimates ranged from 28% (0.00-0.66) to 37% (0.25-0.49), depending on the 246 
assumptions of the genetic model (Table 4). A pure environmental model did not fit the 247 
data. Among current smokers, the heritability was estimated at 29% (0.00-0.74) or 41% 248 
(0.26-0.56), depending on genetic assumptions (Table 4).  249 
Finally, for smoking discordant pairs, we examined whether smoking status was 250 
associated with future lung cancer. In the ever smoking discordant pairs (3,274 MZ pairs 251 
and 8,350 DZ pairs), 40 MZ pairs were discordant for lung cancer (Table 5). Of these 35 252 
cases were among ever smokers (with their non-smoking co-twin being unaffected) and 253 
only five in the never-smokers (while their smoking co-twin was unaffected), yielding a 254 
paired analysis hazard ratio (HR) of 5.4. Results for DZ pairs and for current-smoking 255 
versus never smoking discordant pairs are shown in Table 5. Most discordant pairs arose 256 
from pairs in which the smoker still smoked at baseline. None of the smoking discordant 257 
pairs were concordant for lung cancer.  258 
 259 
260 
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Discussion 261 
In the largest study of lung cancer in twins to date, we found that genetic effects 262 
account for a significant amount of the variation in the liability to develop lung cancer, 263 
and the magnitude of this estimate is independent of smoking status. The largest estimate 264 
of heritability in the liability to lung cancer was found in pairs where both were current 265 
smokers at baseline. Among twin pairs where both twins were never smokers, only one 266 
concordant lung cancer pair was seen and a formal estimate of heritability could not be 267 
derived. A test of gene by smoking interaction was not significant suggesting that the 268 
relative contribution of genetics does not vary by smoking status. Furthermore, testing 269 
suggests that the contribution of familial effects does not increase by age. Our pairwise 270 
analysis of smoking discordant pairs confirmed that smoking causes lung cancer 271 
independent of genetic liability either to smoking or to lung cancer. 272 
Twin pairs discordant for both lung cancer and smoking status at baseline are 273 
informative for causal analyses. In the lung cancer and smoking doubly discordant pairs, 274 
the pairwise relative risk for lung cancer was 5.4 among ever smokers in MZ pairs. It is 275 
of historical interest that after the landmark papers of Doll and Hill27 and Wynder and 276 
Graham28 in the early 1950s, the causality of the relationship between smoking and lung 277 
cancer was soon challenged by the great statistician Ronald Fisher.25 He pointed out the 278 
greater similarity of MZ vs. DZ pairs for smoking, and indicated genetics as a potential 279 
confounder.  MZ pairs discordant for smoking would help to resolve the issue of 280 
causality. Following up on prior twin studies of smoking discordant pairs,29,30 we can 281 
now finally put this issue to rest, an issue debated for many years because of tobacco 282 
industry’s prolonged refusal to acknowledge publicly that smoking causes lung cancer. 283 
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Smoking is the most important cause of lung cancer. Taking smoking into 284 
account permits us to test for the dependence of genetic effects on smoking status. The 285 
overall estimate of familial aggregation (genetic variance and shared environment 286 
component) for lung cancer liability is 44%, with most variability attributed to genetic 287 
effects (38%), higher but still consistent with the estimate 26% (95%CI 0%–49%) by 288 
Lichtenstein et al.3 also unadjusted for smoking and for censoring, but based on a smaller 289 
number of affected pairs. We recently reported on the heritability for liability to lung 290 
cancer in the entire NorTwinCan data, with an overall estimate of familial aggregation of 291 
42%.4 The present analysis extends these estimates by accounting for the effect of 292 
smoking status prior to disease occurrence and examines heritability among the smoking 293 
pairs.  294 
In our analysis, adjustment for smoking eliminates the estimates for shared 295 
environmental effects. Shared environmental effects (i.e. exposure to smokers in the 296 
childhood home, and among peers in adolescence) are of importance for the initiation of 297 
smoking31 so it is not surprising that adjustment for smoking controls for this source of 298 
variation. The highest estimates of heritability and recurrence risks were seen among 299 
current smoking pairs. Among never smokers, we cannot estimate the heritability of lung 300 
cancer.  301 
Prior family2 and twin3,4  studies of lung cancer have demonstrated familial 302 
aggregation and provided very modest estimates for the role of genes. The Swedish 303 
multi-generational register family study2 estimated the heritability of lung cancer to be 304 
8% (95% CI 5%–9%), without information on smoking in the families.   The American 305 
World War II veterans’ study 32 followed 12,938 male twin pairs for 44 years for 306 
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mortality. Among pairs with at least one lung cancer death, only 10 of 269 MZ pairs and 307 
21 of 373 DZ pairs were concordant, and no heritability estimate was provided. Smoking 308 
information was not used in the analysis, but smoking-related cancers showed less MZ –309 
DZ differences in similarity than other cancers. Despite the large number of pairs in our 310 
present study, the final number of concordant pairs with smoking information was 311 
limited. Thus, we could not examine heritability of lung cancer risk in relation to time 312 
trends in lung cancer or histological subtypes of lung cancer. Nor did we have 313 
information on smoking amount, duration or changes in smoking status comprehensively 314 
and comparably assessed in all the twin cohorts. 315 
Since detailed smoking information was not available, it should be acknowledged 316 
as a potential limitation that there might be residual confounding that remains in the 317 
estimates of heritability estimation. Because MZ twins, who are smokers, are also more 318 
similar than DZ pairs in age of smoking initiation, amount smoked and duration of 319 
smoking31, the heritability of lung cancer among smokers may still contain residuals 320 
effects of genetics on smoking, and thus on lung cancer risk.  321 
The overall genetic contribution to lung cancer as a function of smoking status is 322 
relevant for gene discovery.  Since 2007, 21 lung cancer genome-wide analysis (GWA) 323 
and genome-wide meta-analysis studies33 (www.genome.gov/gwastudies) have found the 324 
strongest association to the CHRNA5 functional D398N (rs16969968) variant. The 325 
functional changes34,35 in nicotinic acetylcholine receptor activity are linked to increased 326 
risk for nicotine dependence, higher amount smoked36-39 and higher cotinine levels.40,41 327 
Thus, those with a risk allele smoke more, are more tobacco-dependent and are less likely 328 
to quit, and  therefore at higher risk of developing lung cancer. However, D398N is not a 329 
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risk factor for lung cancer in non-smokers, based on a GWA meta-analysis of 14,900 330 
lung cancer cases and 29,485 controls6 and among 56,037 individuals from the HUNT 331 
population study in Norway.5 This variant requires exposure to smoking to affect lung 332 
cancer risk and thus contributes to the heritability seen among current smokers. In 333 
contrast to D398N, associations with other loci found to be significant for lung cancer 334 
such as those in 5p15 (TERT and CLPTM1L genes) and 6p21 (BAG6/BAT3) are found 335 
also in non-smokers.33,6 The existence of a modest familial liability to lung cancer 336 
independent of smoking status was also observed in the analysis of Utah genealogical 337 
data.42 An increased risk of lung cancer was seen even in distant relatives; the high 338 
proportion of non-smoking lung cancer cases (31%) and a large proportion of missing 339 
data on smoking status (which was assessed through the death certificate and not 340 
prospectively) calls for replication in other populations. A recent large meta-analysis 341 
yielded an array-based heritability estimate for lung cancer of 21% (95% CI 14-27%).43 342 
This is somewhat smaller than our overall twin estimates suggesting that much of the 343 
genetic liability to lung cancer is attributable to common variants, but other genetic 344 
effects may exist. The same study estimated that 24% of the heritability of lung cancer is 345 
accounted for by genetic determinants of smoking behavior. 346 
In conclusion, our study extends earlier studies to examine the heritability in 347 
liability to lung cancer by smoking status and age. We find no formal evidence for a gene 348 
by environmental exposure interaction in lung cancer; more detailed environmental 349 
exposures and larger sample sizes may be required. We hypothesize that a genetic part of 350 
the rather strong familial influence demonstrated may become weaker by age. Studies of 351 
genetic factors and hence molecular mechanisms in cancer would benefit by carefully 352 
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taking into account known environmental risk factors and identifying the population 353 
groups at highest genetic risk using environmental stratification.  However, the discordant 354 
pair analysis conclusively demonstrates that tobacco exposure causes lung cancer even 355 
when adjusting for genetic factors. 356 
357 
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Table 1. Characteristics of the twin cohorts included in the analyses by zygosity and sex 505 
(individuals with smoking data), NorTwinCan 506 
Sex and zygosity 
of twin 
individuals 
Denmark Finland Norway Sweden Total 
Males      
MZ  5,309 3,421 2,532  8,525 19,787 
DZ  8,263 8,035 3,313 14,262  33,873 
UZ     480 1,247 -   1,131    2,858 
All males 14,052    12,703 5,845  23,918   56,519 
Females      
MZ  6,570  3,940 3,074  10,141    23,725 
DZ  9,525  8,092 3,788  16,617    38,022 
UZ     473  1,049 -       996      2,518 
All females      16,568 13,081  6,862  27,754     64,265 
Birth cohort 
included 
1870–1982 1880–1957 1915–1960 1886–1958  
1st Year of 
assessment of 
smoking and start 
of lung cancer 
occurrence 
follow-up 
1959 1975 1980 1961  
End of  follow-up 
for lung cancer 
occurrence 
2010 2011 2009 2010  
Number of 
incident lung 
cancers 
354 341 152 661 1508 
Mean age at 
baseline (years) 
49.0 36.2 38.3 38.9  
Mean follow-up 
time (years) 
10.2* 30.1 24.6 32.1  
 507 
Note: The 5,376 twins with unknown zygosity are included in the table but are 508 
excluded from pairwise analysis. 509 
 510 
*In Denmark, smoking data came from eight surveys conducted from 1959 to 2002.  511 
 512 
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Table 2. The numbers of pairs concordant and discordant for lung cancer at the end of follow-up by baseline pairwise smoking status 513 
and zygosity.  514 
 515 
 Pairwise lung cancer status 
 Monozygotic Dizygotic 
Baseline pairwise  
smoking status 
Number of  
Concordant Pairs 
Number of 
Discordant Pairs 
Number of  
Concordant Pairs 
Number of  
Discordant Pairs 
Concordant pairs for smoking Neither 
affected 
Both 
affected 
One twin in  
the pair affected 
Neither 
affected 
Both 
affected 
One twin in  
the pair affected 
Never / Never 7827 1 43 10709 0 59 
Ever / Ever 7942 29 332 11474 28 527 
Current / Current# 4741 24 241 6341 24 356 
Discordant pairs for smoking       
Never / Ever 3234 0 40 8177 0 173 
Never / Current## 1982 0 35 5511 0 144 
 516 
# Current/current pairs are a subset of ever/ever pairs 517 
## Never/current pairs are a subset of the never/ever pairs. 518 
519 
 27 
 
 520 
Table 3. Heritability estimates for lung cancer in the NorTwinCan cohort among those in the present analysis with smoking data, with 521 
and without adjustment for smoking status (n=1508 cases). All estimates adjusted for country and sex. 522 
 523 
Number 
of 
complete 
MZ/DZ 
pairs 
Casewise concordance rates  
95% Confidence Intervals 
 
Adjustment 
for 
smoking 
Variance component estimates 
95% Confidence Intervals 
MZ DZ A C E 
 
5299 
9359 
 
0.22 
0.15 to 0.29 
 
0.13 
0.09 to 0.17 
No 0.38 
0.05 to 0.72 
0.06 
0.00 to 0.31 
0.55 
0.43 to 0.68 
Yes 0.34 
0.00 to 0.70 
0.02 
0.00 to 0.29 
0.64 
0.50 to 0.78 
 524 
Note: Variance components are: A: additive genetic effects, C: common environmental effects, and E: individually unique 525 
environmental effects estimated from biometrical twin model taking into account censoring (see methods in the online supplement).  526 
 527 
528 
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Table 4. Pairwise correlations in liability, heritability estimates and model fit parameters for liability to incident lung cancer among 529 
ever smoking and current smoking concordant twin pairs from the NorTwinCan study. Estimates of genetic (A), shared environmental 530 
(C), and unshared environmental (E) variance are presented for the ACE, AE, and CE models.  531 
 532 
Model 
Correlation (95% CI) A C E 
AIC p-value  
MZ 
 
DZ 
Estimate 
(95%CI) 
Estimate 
(95%CI) 
Estimate 
(95%CI) 
Ever smokers 
ACE 
 
 
0.35 
(0.21–0.49) 
 
 
0.21 
(0.09–0.33) 
0.28 
(0.0–0.66) 
0.07  
(0.0–0.36) 
0.65 
(0.50–0.79) 
38759.12 
0.011 
AE 
0.37 
(0.25–0.49) 
0 
- 
0.63 
(0.51–0.75) 
38757.92 
0.35 
CE 0 
0.28 
(0.19–0.37) 
0.72 
(0.63–0.81) 
38764.19 
0 
Current  smokers 
ACE 
 
 
0.39 
(0.20–0.55) 
 
 
0.24 
(0.10–0.38) 
0.29 
(0.0–0.74) 
0.10 
(0.0–0.44) 
0.62 
(0.44–0.79) 
30484.27 0.121 
AE 
0.41 
(0.26–0.56) 
0 
- 
0.59 
(0.44–0.74) 
30483.46 
0.27 
CE 0 
0.31 
(0.20–0.42) 
0.69 
(0.58–0.80) 
30488.49 
0.01 
1Compared to saturated model, the other models are compared to ACE model. 533 
2 95%CI for C effect here could not be estimated reliably 534 
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Table 5. Lung cancer in twin pairs discordant for smoking at baseline by zygosity and smoking status 535 
 536 
Smoking 
discordance 
Zygosity Pairs in which smoker had 
lung cancer and the non-
smoking cotwin did not 
Pairs in which non- smoker 
had lung cancer and the 
smoking cotwin did not 
Hazard ratios 
(95% CI) and p-value 
Ever/never MZ 35 5 5.4 ( 2.1–14.0); p=0.0005 
 DZ 145 28 5.0 ( 3.2–7.9); p=1.4e-12 
Current/never MZ  31 4 6.0 (2.1-17.3) p=0.001 
 DZ  124 20 5.9 (3.5-9.8) p=1.4e-11 
 30 
 
Figure legends 
 
Figure 1. Cumulative incidence of lung cancer by smoking status (never, former, current) 
and sex (male, female). Cumulative incidence curves are adjusted for censoring, delayed 
entry to cancer registration, and competing risk of death. (Continuous lines are for never 
smokers, dashed lines for former smokers and dotted lines for current smokers; black for 
males and red for females). 
 
Figure 2. Case-wise concordance risk of lung cancer in MZ and DZ pairs compared to 
population risk among ever smokers, by age at diagnosis.  
 
Figure 3.  Relative recurrence risk ratio of lung cancer in MZ and DZ pairs compared to 
population risk among ever smokers, by age at diagnosis.  
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